Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

A local resident receives the Moderna COVID-19 vaccine shot at a center, June 30, 2021, in the Sumida ward of Tokyo. (Eugene ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

FILE - A local resident receives the Moderna COVID-19 vaccine shot at a center, June 30, 2021, in the Sumida ward of Tokyo. (AP Photo/Eugene Hoshiko, File)(Eugene Hoshiko / AP) Moderna cut its ...

The majority of those sales will come from Moderna's Covid shot and newly launched vaccine for respiratory syncytial virus, according to a release. The guidance is down from a prior forecast range ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Against the backdrop of poor sales of the company’s COVID-19 shot Spikevax and its RSV prophylactic mRESVIA, Moderna is “accelerating and expanding” its prior cost efficiency and ...

Moderna's massive covid vaccine sales and prepayments left ... The convenience of a combination shot could draw some of the 150 million Americans who receive a flu shot each year to receive ...